Dishman Carbogen Amcis' Naroda facility gets zero observations

The inspection was concluded without any observations or Form 483's, thus confirming that no concerns were discovered during the inspection, the company mentioned in the exchange filing.

Feb 15, 2019 09:02 IST India Infoline News Service

Dishman Pharmaceuticals
Dishman Carbogen Amcis announced in an exchange filing that the USFDA inspection of company's facility at Naroda, Ahmedabad, has been successfully completed on 15th February, 2019.

“The inspection was concluded without any observations or Form 483's, thus confirming that no concerns were discovered during the inspection,” the company mentioned in the exchange filing.

The company also mentioned that its facilities in Bavla and Naroda in India and multiple facilities in Switzerland and the Netherlands continue to be approved by the USFDA.

Dishman Carbogen Amicis Limited is an India-based contract research and manufacturing services (CRAMS) company. The Company is engaged in the process of research and development to late-stage clinical and commercial manufacturing.

Dishman Carbogen Amcis Ltd is currently trading at Rs189.15 up by Rs6.65 or 3.64% from its previous closing of Rs182.50 on the BSE.

The scrip opened at Rs183.50 and has touched a high and low of Rs195 and Rs182.10 respectively. So far 1,98,970 (NSE+BSE) shares were traded on the counter. 

Related Story